2026-08-29T10:11:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/172962024-11-28T15:08:19Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Torres, M J author Romano, A author Celik, G author Demoly, P author Khan, D A author Macy, E author Park, M author Blumenthal, K author Aberer, W author Castells, M author Barbaud, A author Mayorga, C author Bonadonna, P author 2017-03-13 Drug hypersensitivity reactions (DHRs) affect an unknown proportion of the general population, and are an important public health problem due to their potential to cause life-threatening anaphylaxis and rare severe cutaneous allergic reactions. DHR evaluations are frequently needed in both ambulatory and hospital settings and have a complex diagnosis that requires a detailed clinical history and other tests that may include in vitro tests and in vivo procedures such as skin tests and drug provocation tests. Although over the years both European and U.S. experts have published statements on general procedures for evaluating DHRs, a substantial discordance in their daily management exists. In this review, we highlight both the differences and the similarities between the European and U.S. 10.1186/s13601-017-0144-0 2045-7022 Clinical and Translational Allergy http://hdl.handle.net/10668/2681 28293415 http://hdl.handle.net/20.500.12105/17296 Drug Hypersensitivity Allergy Diagnosis Skin test In vitro test IgE T-cells Drug provocation test Sensitization Unit States Europe Anafilaxia Evaluación de Medicamentos Hipersensibilidad a las drogas Grupos étnicos Humanos Salud pública Pruebas cutáneas Estados Unidos Europa Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America